Dana-Farber Cancer Institute

This is your central portal for breaking news, the latest research and important updates from Dana-Farber Cancer Institute. Bookmark this page and check back often for updates.


Should lenvatinib be used as first-line therapy for slowly progressing radioiodine-refractory thyroid carcinoma?

HemOnc Today, July 10, 2019
POINT Lenvatinib is my preference as a first-line therapy when patients need treatment beyond levothyroxine and thyroid-stimulating hormone suppression.
Meeting NewsVideo

VIDEO: Tumor size, node status, age affect risk for breast cancer mortality

July 10, 2019
CHICAGO — At the ASCO Annual Meeting, Jose Pablo Leone, MD, medical oncologist at Dana-Farber Cancer Institute, spoke with HemOnc Today
Meeting NewsVideo

VIDEO: Eribulin plus pembrolizumab shows no clinical benefit in breast cancer subtype

July 2, 2019
CHICAGO — The addition of pembrolizumab to eribulin demonstrated no significant improvements in terms of PFS, OS or objective response rate…
In the Journals

High cardiac radiation dose may increase mortality odds in patients with lung cancer

July 2, 2019
Among patients with non-small cell lung cancer, a higher cardiac radiation dose may lead to elevated risk for major adverse cardiac events and…

OncoSec, Dana-Farber strike exclusive rights agreement for CAR T-cell technology

June 30, 2019
OncoSec Medical has announced a collaborative agreement with Dana-Farber Cancer Institute for the development of chimeric antigen receptor T-cell…

Dana-Farber clinic to focus on blood cancer precursor conditions

June 28, 2019
Dana-Farber Cancer Institute opened a new clinic designed to improve clinical care and monitoring for individuals with precursor conditions that can…
In the Journals

FDA-approved cancer drugs take more than 6 years to reach children

June 25, 2019
FDA-approved oncology agents took a median 6.5 years to proceed from first-in-human to first-in-child clinical trials, according to research…
Cover Story

Despite promising new regimens, search for cure is ‘highest priority’ in advanced renal cell carcinoma

HemOnc Today, June 25, 2019
With approximately 73,820 diagnoses and 14,770 deaths expected this year in the U.S., renal cell carcinoma remains a cancer in need of new treatment…
In the Journals

Walking speed, grip strength predict outcomes among older patients with blood cancers

June 21, 2019
Walking speed appeared to be an important predictor of survival and hospital utilization among older patients with hematologic malignancies…
Meeting NewsVideo

VIDEO: Talazoparib improves PFS in patients with BRCA mutations

June 20, 2019
CHICAGO — At the ASCO Annual Meeting, Jose Pablo Leone, MD, medical oncologist at Dana-Farber Cancer Institute, spoke with HemOnc Today

Dana-Farber/Boston Children’s named nation’s best hospital for pediatric cancer

June 18, 2019
Dana-Farber/Boston Children’s Cancer and Blood Disorders Center has reclaimed its distinction as the No. 1 children’s hospital for cancer…
Meeting NewsPerspective

Triplet therapy confers benefit among certain patients with advanced breast cancer

June 13, 2019
CHICAGO — The combination of ribociclib, everolimus and exemestane conferred clinical benefit and appeared tolerable among patients with…
Meeting NewsPerspective

Enzalutamide improves OS for metastatic hormone-sensitive prostate cancer

June 10, 2019
CHICAGO — Enzalutamide used in combination with standard therapy significantly improved OS compared with other nonsteroidal antiandrogen drugs…
Meeting News

Conquer Cancer Foundation presents Merit Awards at ASCO

June 6, 2019
CHICAGO — The Conquer Cancer Foundation of ASCO presented ASCO Annual Meeting Merit Awards to more than 100 oncology professionals. The awards…
Meeting NewsPerspective

Isatuximab regimen extends PFS in relapsed, refractory multiple myeloma

June 5, 2019
CHICAGO — The addition of isatuximab to pomalidomide and low-dose dexamethasone significantly improved PFS and overall response rate among…
Meeting News

Neoadjuvant atezolizumab shows promise in non-small cell lung cancer

June 4, 2019
CHICAGO — Neoadjuvant atezolizumab induced sustained responses in patients with operable non-small cell lung cancer, according to results from…
In the Journals

Daratumumab regimen reduces risk for progression, death in newly diagnosed multiple myeloma

May 30, 2019
The addition of daratumumab to lenalidomide and dexamethasone significantly decreased the risk for disease progression or death among patients with…
In the Journals

Black men less likely to adopt active surveillance, watchful waiting for low-risk prostate cancer

May 22, 2019
Black men appeared less likely to adopt conservative management of low-risk prostate cancer with watchful waiting or active surveillance than…
In the JournalsPerspective

Functional impairment linked to higher mortality among older adults with hematologic malignancies

May 9, 2019
Older adults with hematologic malignancies who require assistance with at least one basic or instrumental daily living activity have a higher risk…
In the JournalsPerspective

Vitamin D supplementation shows limited benefit in patients with gastrointestinal cancers

May 3, 2019
Vitamin D3 supplementation moderately prolonged PFS and, to a limited extent, RFS among patients with certain gastrointestinal cancers, according to…